If you’ve been told you have a “fatty liver” or the newer term MASH (metabolic dysfunction–associated steatohepatitis), you’re not alone—and you’re not stuck. MASH is rising fast alongside weight gain, insulin resistance, and type 2 diabetes. For years, everyday advice—lose weight, move more, watch carbs—was the only path forward. Important, yes, but often not enough. Now, there’s a game-changer: semaglutide (Wegovy) has received FDA approval to treat MASH with liver fibrosis, giving primary care teams and patients a powerful new option alongside nutrition, movement, and metabolic care.

Tired, Gaining Weight, and Don’t Know Why?

You’re not lazy. You’re not undisciplined. But no matter how hard you try, the weight doesn’t come off, the energy never lasts, and you just don’t feel like yourself.

Sound familiar?

You’re not alone—and you’re not just “getting older.” Many of the patients we care for at Innovative Primary Care in San Antonio, Rockport, and Bandera, Texas (as well as through virtual visits) come to us with these same concerns. The truth is, it’s often hormonal imbalance, not age, that’s behind your symptoms.